Artificial Intelligence, Deeptech, Healthcare
Monetization
Audience
Tags
Digital, Social Impact
Company address
Via Pellizzi 11, Pisa
Company number
IT02431380506
Website
Schedule a call
N.A.
Breast Cancer is the most frequent type of cancer among women, representing 25% of all the cancers. One woman out of 8 is affected by Breast Cancer along her life. In this context, prevention and early detection of cancer has proven to be crucial: breast screening has therefore become a regular practice, supported by HealthCare systems and covered by protected budgets from SSA (Social Security Administration). Breast screening is performed on the whole range of women population after a certain age, for example in Italy after the age of 45 years. Worldwide 300 million women every year are subject to breast screenings. That’s the reason why we created DeepMammo, a technology based on eXplainable and Generative AI that empowers radiologists in early detection of Breast Cancer. DeepMammo is based on a proprietary technology, which has been registered as a trademark and patented. Exploiting proprietary MultiModal Deep Neural Networks, DeepMammo supports Imaging workflows augmenting radiologists’ performances, improving accuracy, safety, cost-effectiveness and patient journey: it helps mitigate the shortage of radiologists, therefore improving clinical practice in Breast Cancer screenings. Finally, by reducing the cancer screening time and envisaging a personalized screening method, it simplify and speed-up daily screening activities. Doing so, we save women lives.
Read More-
Nov, 202300 00 00
-
Dec, 202300 00 00
-
Jun, 202400 00 00
Receive premium dealflow
Claim your account now!
Company | Why we are better |
---|---|
Kheiron Medical |
00 00 00
|
ScreenPoint |
00 00 00
|
Lunit |
00 00 00
|
# Paying Customers |
00 00 00
|
Revenue (EUR) |
00 00 00
|
CAGR |
00 00 00
%
|
CMGR |
00 00 00
%
|
LTV (EUR) |
00 00 00
|
CAC (EUR) |
00 00 00
|
ARR (EUR) |
00 00 00
|
Monthly burn (EUR) |
00 00 00
|
Runway in months |
00 00 00
|
Gross profit margin |
00 00 00
%
|
Net profit margin |
00 00 00
%
|
Projected Financials

Historical Financials

Use of Capital

Type | Date | Amount | Round | Organizations | Valuation | Status |
---|---|---|---|---|---|---|
Grant | 2024-03-01 |
00 00 00
EUR
|
00 00 00
|
00 00 00
|
00 00 00
|
00 00 00
|
Equity | 2023-06-01 |
00 00 00
EUR
|
00 00 00
|
00 00 00
|
00 00 00
|
00 00 00
|
Investor | Type | Issued Shares | Stock Options | % Issued Shares | % Fully Diluted Shares |
---|---|---|---|---|---|
Federico Picardi |
00 00 00
|
00 00 00
|
00 00 00
|
00 00 00
|
00 00 00
|
Carlo Aliprandi |
00 00 00
|
00 00 00
|
00 00 00
|
00 00 00
|
00 00 00
|
Extra Group |
00 00 00
|
00 00 00
|
00 00 00
|
00 00 00
|
00 00 00
|
Total | 0 | 0 | 0% | 0% |
Request pitch deck and financials.
Gain access to dig deeper into this opportunity!
Request full dataroom access.
Everything you need to close the deal!